NSCLC Stage IV
104
26
35
17
Key Insights
Highlights
Success Rate
55% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
13.5%
14 terminated out of 104 trials
54.8%
-31.7% vs benchmark
3%
3 trials in Phase 3/4
35%
6 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (104)
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Plasma-Adapted First-Line Pembro In NSCLC
Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer